메뉴 건너뛰기




Volumn 65, Issue 16, 2015, Pages 1619-1629

Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: The ISAR-TRIPLE trial

Author keywords

aspirin; atrial fibrillation; clopidogrel; percutaneous coronary intervention; vitamin K antagonist

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

EID: 84928024668     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.02.050     Document Type: Article
Times cited : (377)

References (35)
  • 1
    • 77958128969 scopus 로고    scopus 로고
    • Guidelines on myocardial revascularization
    • W. Wijns, P. Kolh, and N. Danchin et al. Guidelines on myocardial revascularization Eur Heart J 31 2010 2501 2555
    • (2010) Eur Heart J , vol.31 , pp. 2501-2555
    • Wijns, W.1    Kolh, P.2    Danchin, N.3
  • 2
    • 9244251971 scopus 로고    scopus 로고
    • A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
    • A. Schomig, F.J. Neumann, and A. Kastrati et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents N Engl J Med 334 1996 1084 1089
    • (1996) N Engl J Med , vol.334 , pp. 1084-1089
    • Schomig, A.1    Neumann, F.J.2    Kastrati, A.3
  • 3
    • 33744945247 scopus 로고    scopus 로고
    • Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial
    • S. Connolly, J. Pogue, and R. Hart et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
    • (2006) Lancet , vol.367 , pp. 1903-1912
    • Connolly, S.1    Pogue, J.2    Hart, R.3
  • 4
    • 0037464819 scopus 로고    scopus 로고
    • Clopidogrel and Aspirin in the Prevention of Thromboembolic Complications After Mechanical Aortic Valve Replacement (CAPTA)
    • A. Schlitt, R.S. von Bardeleben, and A. Ehrlich et al. Clopidogrel and Aspirin in the Prevention of Thromboembolic Complications After Mechanical Aortic Valve Replacement (CAPTA) Thromb Res 109 2003 131 135
    • (2003) Thromb Res , vol.109 , pp. 131-135
    • Schlitt, A.1    Von Bardeleben, R.S.2    Ehrlich, A.3
  • 5
    • 80053177375 scopus 로고    scopus 로고
    • Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective
    • D.P. Faxon, J.W. Eikelboom, and P.B. Berger et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective Thromb Haemost 106 2011 572 584
    • (2011) Thromb Haemost , vol.106 , pp. 572-584
    • Faxon, D.P.1    Eikelboom, J.W.2    Berger, P.B.3
  • 6
    • 84921312430 scopus 로고    scopus 로고
    • Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)
    • G.Y. Lip, S. Windecker, and K. Huber et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS) Eur Heart J 35 2014 3155 3179
    • (2014) Eur Heart J , vol.35 , pp. 3155-3179
    • Lip, G.Y.1    Windecker, S.2    Huber, K.3
  • 7
    • 70349896556 scopus 로고    scopus 로고
    • Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period
    • S. Schulz, T. Schuster, and J. Mehilli et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period Eur Heart J 30 2009 2714 2721
    • (2009) Eur Heart J , vol.30 , pp. 2714-2721
    • Schulz, S.1    Schuster, T.2    Mehilli, J.3
  • 8
    • 84865863475 scopus 로고    scopus 로고
    • Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study
    • M. Lamberts, J.B. Olesen, and M.H. Ruwald et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study Circulation 126 2012 1185 1193
    • (2012) Circulation , vol.126 , pp. 1185-1193
    • Lamberts, M.1    Olesen, J.B.2    Ruwald, M.H.3
  • 9
    • 65249134915 scopus 로고    scopus 로고
    • Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation
    • J.M. Ruiz-Nodar, F. Marin, and J. Sanchez-Paya et al. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation Eur Heart J 30 2009 932 939
    • (2009) Eur Heart J , vol.30 , pp. 932-939
    • Ruiz-Nodar, J.M.1    Marin, F.2    Sanchez-Paya, J.3
  • 10
    • 53649098316 scopus 로고    scopus 로고
    • Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation
    • N. Sarafoff, G. Ndrepepa, and J. Mehilli et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation J Intern Med 264 2008 472 480
    • (2008) J Intern Med , vol.264 , pp. 472-480
    • Sarafoff, N.1    Ndrepepa, G.2    Mehilli, J.3
  • 11
    • 84913619061 scopus 로고    scopus 로고
    • 2014 ESC/EACTS Guidelines on Myocardial Revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
    • S. Windecker, P. Kolh, and F. Alfonso et al. 2014 ESC/EACTS Guidelines on Myocardial Revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 35 2014 2541 2619
    • (2014) Eur Heart J , vol.35 , pp. 2541-2619
    • Windecker, S.1    Kolh, P.2    Alfonso, F.3
  • 12
    • 84908220640 scopus 로고    scopus 로고
    • 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society
    • C.T. January, L.S. Wann, and J.S. Alpert et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 64 2014 e1 e76
    • (2014) J Am Coll Cardiol , vol.64 , pp. e1-e76
    • January, C.T.1    Wann, L.S.2    Alpert, J.S.3
  • 13
    • 84875720372 scopus 로고    scopus 로고
    • Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial
    • W.J. Dewilde, T. Oirbans, and F.W. Verheugt et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 2013 1107 1115
    • (2013) Lancet , vol.381 , pp. 1107-1115
    • Dewilde, W.J.1    Oirbans, T.2    Verheugt, F.W.3
  • 14
    • 84897103441 scopus 로고    scopus 로고
    • Rationale and design of the Intracoronary Stenting and Antithrombotic Regimen-Testing of a 6-Week Versus a 6-Month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-Eluting Stenting (ISAR-TRIPLE) study
    • K.A. Fiedler, R.A. Byrne, and S. Schulz et al. Rationale and design of the Intracoronary Stenting and Antithrombotic Regimen-Testing of a 6-Week Versus a 6-Month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-Eluting Stenting (ISAR-TRIPLE) study Am Heart J 167 2014 459 465.e1
    • (2014) Am Heart J , vol.167 , pp. 459e1-465e1
    • Fiedler, K.A.1    Byrne, R.A.2    Schulz, S.3
  • 15
    • 34247558672 scopus 로고    scopus 로고
    • Clinical end points in coronary stent trials: a case for standardized definitions
    • D.E. Cutlip, S. Windecker, and R. Mehran et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
    • (2007) Circulation , vol.115 , pp. 2344-2351
    • Cutlip, D.E.1    Windecker, S.2    Mehran, R.3
  • 16
    • 79959550517 scopus 로고    scopus 로고
    • Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium
    • R. Mehran, S.V. Rao, and D.L. Bhatt et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
    • (2011) Circulation , vol.123 , pp. 2736-2747
    • Mehran, R.1    Rao, S.V.2    Bhatt, D.L.3
  • 17
    • 80053207003 scopus 로고    scopus 로고
    • Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe
    • K. Huber, K.J. Airaksinen, T. Cuisset, F. Marin, A. Rubboli, and G.Y. Lip Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe Thromb Haemost 106 2011 569 571
    • (2011) Thromb Haemost , vol.106 , pp. 569-571
    • Huber, K.1    Airaksinen, K.J.2    Cuisset, T.3    Marin, F.4    Rubboli, A.5    Lip, G.Y.6
  • 18
    • 84926332974 scopus 로고    scopus 로고
    • ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting
    • E-pub ahead of print
    • S. Schulz-Schüpke, R.A. Byrne, J.M. Ten Berg on behalf of the Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) trial investigators ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting Eur Heart J 2015 Jan 23 [E-pub ahead of print]
    • (2015) Eur Heart J
    • Schulz-Schüpke, S.1    Byrne, R.A.2    Ten Berg, J.M.3
  • 19
    • 84918772240 scopus 로고    scopus 로고
    • Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents
    • L. Mauri, D.J. Kereiakes, and R.W. Yeh et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N Engl J Med 371 2014 2155 2166
    • (2014) N Engl J Med , vol.371 , pp. 2155-2166
    • Mauri, L.1    Kereiakes, D.J.2    Yeh, R.W.3
  • 20
    • 84871258027 scopus 로고    scopus 로고
    • Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials
    • S. Cassese, R.A. Byrne, T. Tada, L.A. King, and A. Kastrati Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials Eur Heart J 33 2012 3078 3087
    • (2012) Eur Heart J , vol.33 , pp. 3078-3087
    • Cassese, S.1    Byrne, R.A.2    Tada, T.3    King, L.A.4    Kastrati, A.5
  • 21
    • 84890373385 scopus 로고    scopus 로고
    • Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial
    • F. Feres, R.A. Costa, and A. Abizaid et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 2013 2510 2522
    • (2013) JAMA , vol.310 , pp. 2510-2522
    • Feres, F.1    Costa, R.A.2    Abizaid, A.3
  • 22
    • 84893651614 scopus 로고    scopus 로고
    • Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial
    • C.W. Lee, J.M. Ahn, and D.W. Park et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial Circulation 129 2014 304 312
    • (2014) Circulation , vol.129 , pp. 304-312
    • Lee, C.W.1    Ahn, J.M.2    Park, D.W.3
  • 23
    • 84905644962 scopus 로고    scopus 로고
    • Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation
    • S. Silber, A.J. Kirtane, and J.A. Belardi et al. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation Eur Heart J 35 2014 1949 1956
    • (2014) Eur Heart J , vol.35 , pp. 1949-1956
    • Silber, S.1    Kirtane, A.J.2    Belardi, J.A.3
  • 24
    • 38949179203 scopus 로고    scopus 로고
    • Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point
    • G. Ndrepepa, P.B. Berger, and J. Mehilli et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point J Am Coll Cardiol 51 2008 690 697
    • (2008) J Am Coll Cardiol , vol.51 , pp. 690-697
    • Ndrepepa, G.1    Berger, P.B.2    Mehilli, J.3
  • 25
    • 84858661398 scopus 로고    scopus 로고
    • Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention
    • G. Ndrepepa, T. Schuster, and M. Hadamitzky et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention Circulation 125 2012 1424 1431
    • (2012) Circulation , vol.125 , pp. 1424-1431
    • Ndrepepa, G.1    Schuster, T.2    Hadamitzky, M.3
  • 26
    • 44249122195 scopus 로고    scopus 로고
    • Bivalirudin during primary PCI in acute myocardial infarction
    • G.W. Stone, B. Witzenbichler, and G. Guagliumi et al. Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
    • (2008) N Engl J Med , vol.358 , pp. 2218-2230
    • Stone, G.W.1    Witzenbichler, B.2    Guagliumi, G.3
  • 27
    • 39149105940 scopus 로고    scopus 로고
    • Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis
    • J.M. Ruiz-Nodar, F. Marin, and J.A. Hurtado et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis J Am Coll Cardiol 51 2008 818 825
    • (2008) J Am Coll Cardiol , vol.51 , pp. 818-825
    • Ruiz-Nodar, J.M.1    Marin, F.2    Hurtado, J.A.3
  • 28
    • 80052162121 scopus 로고    scopus 로고
    • Apixaban with antiplatelet therapy after acute coronary syndrome
    • J.H. Alexander, R.D. Lopes, and S. James et al. Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
    • (2011) N Engl J Med , vol.365 , pp. 699-708
    • Alexander, J.H.1    Lopes, R.D.2    James, S.3
  • 29
    • 84862907587 scopus 로고    scopus 로고
    • Rivaroxaban in patients with a recent acute coronary syndrome
    • J.L. Mega, E. Braunwald, and S.D. Wiviott et al. Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
    • (2012) N Engl J Med , vol.366 , pp. 9-19
    • Mega, J.L.1    Braunwald, E.2    Wiviott, S.D.3
  • 30
    • 84867050148 scopus 로고    scopus 로고
    • A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Endeavor Zotarolimus-Eluting Stent Implantation)
    • B.K. Kim, M.K. Hong, and D.H. Shin et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Endeavor Zotarolimus-Eluting Stent Implantation) J Am Coll Cardiol 60 2012 1340 1348
    • (2012) J Am Coll Cardiol , vol.60 , pp. 1340-1348
    • Kim, B.K.1    Hong, M.K.2    Shin, D.H.3
  • 31
    • 84856452781 scopus 로고    scopus 로고
    • Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study
    • H.C. Gwon, J.Y. Hahn, and K.W. Park et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study Circulation 125 2012 505 513
    • (2012) Circulation , vol.125 , pp. 505-513
    • Gwon, H.C.1    Hahn, J.Y.2    Park, K.W.3
  • 32
    • 84873569160 scopus 로고    scopus 로고
    • Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial
    • A.L. Dans, S.J. Connolly, and L. Wallentin et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial Circulation 127 2013 634 640
    • (2013) Circulation , vol.127 , pp. 634-640
    • Dans, A.L.1    Connolly, S.J.2    Wallentin, L.3
  • 33
    • 84877762403 scopus 로고    scopus 로고
    • Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation
    • N. Sarafoff, A. Martischnig, and J. Wealer et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation J Am Coll Cardiol 61 2013 2060 2066
    • (2013) J Am Coll Cardiol , vol.61 , pp. 2060-2066
    • Sarafoff, N.1    Martischnig, A.2    Wealer, J.3
  • 34
    • 70149101223 scopus 로고    scopus 로고
    • Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    • L. Wallentin, R.C. Becker, and A. Budaj et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
    • (2009) N Engl J Med , vol.361 , pp. 1045-1057
    • Wallentin, L.1    Becker, R.C.2    Budaj, A.3
  • 35
    • 84918810121 scopus 로고    scopus 로고
    • Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy: the SECURITY randomized clinical trial
    • A. Colombo, A. Chieffo, and A. Frasheri et al. Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy: the SECURITY randomized clinical trial J Am Coll Cardiol 64 2014 2086 2097
    • (2014) J Am Coll Cardiol , vol.64 , pp. 2086-2097
    • Colombo, A.1    Chieffo, A.2    Frasheri, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.